Faron Pharmaceuticals updates on immunotherapy candidate bexmarilimab
1 report, 1 independent
Updated Oct 8
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Faron Pharmaceuticals held its R&D Day on October 8, 2026. The company provided an update on its lead immunotherapy candidate, bexmarilimab, and its clinical programs in hematological cancers and solid tumors. The event also featured presentations from clinical experts discussing current treatment challenges in areas of unmet medical need.
From pr-inside.com
Why it matters
The R&D Day offered participants an in-depth look at the scientific foundation and clinical development strategy of bexmarilimab. This provides insight into the commercial opportunity represented by Faron's expanding oncology pipeline.
From pr-inside.com
Who's involved
Keep exploring
The entities involved
-
Yale Cancer Center
hospital in Connecticut, United States
Nothing else this week.